Meeting Report

Breast Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Jacquelyn Lauria, RN, APN, AOCNP® and Rose DiMarco, PharmD, BCPS, BCOP


J Adv Pract Oncol 2022;13(6):570-578 | https://doi.org/10.6004/jadpro.2022.13.6.2 | © 2022 Harborside™


  

ABSTRACT

Jacquelyn Lauria, RN, APN, AOCNP®, of Rutgers Cancer Institute, discusses results from the DESTINY-BREAST04 trial on HER2-low metastatic breast cancer, findings on sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer, and options for disease progression after a CDK4/6 inhibitor. Rose DiMarco, PharmD, BCPS, BCOP, of Thomas Jefferson University Hospital, considers insights provided by a survey on participation in clinical trials among Black patients with metastatic breast cancer.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.